Accéder au contenu
Merck
  • Meta-analysis comparing carvedilol versus metoprolol for the prevention of postoperative atrial fibrillation following coronary artery bypass grafting.

Meta-analysis comparing carvedilol versus metoprolol for the prevention of postoperative atrial fibrillation following coronary artery bypass grafting.

The American journal of cardiology (2013-12-18)
James J DiNicolantonio, Craig J Beavers, Arthur R Menezes, Carl J Lavie, James H O'Keefe, Pascal Meier, András Vorobcsuk, Dániel Aradi, András Komócsi, Saurav Chatterjee, Fabrizio D'Ascenzo, Mauro Gasparini, Jasper Brugts, Giuseppe Biondi-Zoccai
RÉSUMÉ

A systematic review and meta-analysis was performed to evaluate the effects of carvedilol versus metoprolol on the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting in randomized controlled trials. Ovid MEDLINE, PubMed, CENTRAL, and Excepta Medica (EMBASE) were searched up to March 2013 for suitable randomized controlled trials. Data were pooled using random-effects model for pairwise analyses. A total of 4 trials with 601 patients were included in this analysis. Pairwise analyses showed that compared with metoprolol, carvedilol significantly reduced the incidence of postoperative atrial fibrillation (odds ratio 0.50, 95% confidence interval 0.32 to 0.80). In conclusion, compared with metoprolol, carvedilol significantly reduces the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Carvedilol, ≥98% (HPLC), solid
USP
Carvedilol, United States Pharmacopeia (USP) Reference Standard
Supelco
Carvedilol, Pharmaceutical Secondary Standard; Certified Reference Material
Carvedilol for system suitability, European Pharmacopoeia (EP) Reference Standard
Carvedilol, European Pharmacopoeia (EP) Reference Standard